PTJ
CADX

Paul Tudor Jones’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Paul Tudor Jones’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-16,706
Closed -$151K – 1601
2013
Q4 		$151K Sell
16,706
-13,994
-46% -$101K 0.01% 1155
2013
Q3 		$193K Buy
+30,700
New +$195K 0.01% 744

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Paul Tudor Jones's CADX Position: Q1 2014 in Review

Paul Tudor Jones sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 16,706 shares — an estimated $151K sold.

Paul Tudor Jones first reported a position in CADX in Q3 2013 and held it in 2 quarters. The position peaked at $193K in Q3 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Paul Tudor Jones reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Paul Tudor Jones sold 16,706 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $151K.
  • Paul Tudor Jones first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q3 2013 and held it in 2 quarters.
  • Paul Tudor Jones's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $193K in Q3 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Tudor Investment Corp's 13F filing for Q1 2014, filed 15 May 2014.